The Investor
05 Nov 2026, 15:13
BD Rises 2.2% as Q4 Growth and Strong Cash Flow Support Fiscal 2027 Outlook
Becton, Dickinson and Company (NYSE: BDX) shares rose about 2.2% after the medical technology company reported solid fourth-quarter growth and strong cash generation following the separation of its former Life Sciences business.
Fourth-quarter revenue increased 5.4% to $5.3 billion, or 5.6% on a currency-neutral basis. Adjusted diluted EPS was $4.15.
For fiscal 2026, revenue rose 4.9% to $19.5 billion, while adjusted EPS reached $12.70. Cash from continuing operations increased 30% to $3.6 billion, and free cash flow jumped 42.5% to $2.9 billion.
BD said growth was broad-based across its key platforms and highlighted its transformation into a more focused MedTech company after completing the spin-off and combination of its former Biosciences and Diagnostic Solutions business with Waters.
For fiscal 2027, BD expects low-single-digit revenue growth and adjusted EPS of $13.10-$13.30.
The 2.2% share gain appears to reflect resilient fourth-quarter growth, sharply stronger free cash flow and confidence in the earnings profile of the streamlined business, despite relatively modest revenue growth guidance for fiscal 2027.
Becton, Dickinson and Company (NYSE: BDX) shares rose about 2.2% after the medical technology company reported solid fourth-quarter growth and strong cash generation following the separation of its former Life Sciences business.
Fourth-quarter revenue increased 5.4% to $5.3 billion, or 5.6% on a currency-neutral basis. Adjusted diluted EPS was $4.15.
For fiscal 2026, revenue rose 4.9% to $19.5 billion, while adjusted EPS reached $12.70. Cash from continuing operations increased 30% to $3.6 billion, and free cash flow jumped 42.5% to $2.9 billion.
BD said growth was broad-based across its key platforms and highlighted its transformation into a more focused MedTech company after completing the spin-off and combination of its former Biosciences and Diagnostic Solutions business with Waters.
For fiscal 2027, BD expects low-single-digit revenue growth and adjusted EPS of $13.10-$13.30.
The 2.2% share gain appears to reflect resilient fourth-quarter growth, sharply stronger free cash flow and confidence in the earnings profile of the streamlined business, despite relatively modest revenue growth guidance for fiscal 2027.
